190 related articles for article (PubMed ID: 37180644)
1. Effectiveness of tislelizumab when combined with etoposide and carboplatin in patients with SMARCA4-deficient undifferentiated thoracic tumor: a case report.
Yang P; Xiong F; Lin Y; Liang P; Tang C
Transl Cancer Res; 2023 Apr; 12(4):1041-1048. PubMed ID: 37180644
[TBL] [Abstract][Full Text] [Related]
2. [Thoracic
Xiong Y; Zhang B; Nie LG; Wu SK; Zhao H; Li D; DI JT
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):351-356. PubMed ID: 37042149
[TBL] [Abstract][Full Text] [Related]
3. Case report: A rapid response to immunotherapy in a thoracic SMARCA4-deficient undifferentiated tumor with respiratory failure.
Shi L; Lin L; Ding Y; Zeng Y; Chen X
Front Oncol; 2022; 12():1020875. PubMed ID: 36452500
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment with tislelizumab plus chemotherapy for SMARCA4-deficient undifferentiated tumor: a case report.
Dong W; Dai A; Wu Z; Wang J; Wu T; Du Y; Tian W; Zheng J; Zhang Y; Wang H; Cai J; Dong S; Zhou Y; Li S; Xiao Z
Front Immunol; 2024; 15():1371379. PubMed ID: 38881888
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma.
Kawachi H; Kunimasa K; Kukita Y; Nakamura H; Honma K; Kawamura T; Inoue T; Tamiya M; Kuhara H; Nishino K; Mizote Y; Akazawa T; Tahara H; Kumagai T
Immunotherapy; 2021 Jul; 13(10):799-806. PubMed ID: 34030451
[TBL] [Abstract][Full Text] [Related]
6. Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
Zhou P; Fu Y; Tang Y; Jiang L; Wang W
Lung Cancer; 2024 Mar; 189():107471. PubMed ID: 38306886
[TBL] [Abstract][Full Text] [Related]
7. Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report.
Kunimasa K; Okami J; Takenaka S; Honma K; Kukita Y; Nagata S; Kawamura T; Inoue T; Tamiya M; Kuhara H; Nishino K; Tahara H; Kumagai T
JTO Clin Res Rep; 2021 Nov; 2(11):100235. PubMed ID: 34746887
[TBL] [Abstract][Full Text] [Related]
8. Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor.
Lin Y; Yu B; Sun H; Zhang H; Hu Z; Zhang Y; Wu Z; Sun S; Zhao X; Yu H; Wu X; Li Y; Wang J; Wang H
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8663-8671. PubMed ID: 37115272
[TBL] [Abstract][Full Text] [Related]
9. A case of surgically treated non-metastatic SMARCA4-deficient undifferentiated thoracic tumor: a case report and literature review.
Yin C; Liu ZJ; He C; Yu HX
Front Oncol; 2024; 14():1399868. PubMed ID: 38903719
[TBL] [Abstract][Full Text] [Related]
10. Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
Gantzer J; Davidson G; Vokshi B; Weingertner N; Bougoüin A; Moreira M; Lindner V; Lacroix G; Mascaux C; Chenard MP; Bertucci F; Davidson I; Kurtz JE; Sautès-Fridman C; Fridman WH; Malouf GG
Oncologist; 2022 Jun; 27(6):501-511. PubMed ID: 35278076
[TBL] [Abstract][Full Text] [Related]
11. Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods.
Shi M; Pang L; Zhou H; Mo S; Sheng J; Zhang Y; Liu J; Sun D; Gong L; Wang J; Zhuang W; Huang Y; Chen Z; Zhao Y; Li J; Huang Y; Yang Y; Fang W; Zhang L
Lung Cancer; 2024 Jun; 192():107818. PubMed ID: 38763102
[TBL] [Abstract][Full Text] [Related]
12. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor.
Nambirajan A; Jain D
Semin Diagn Pathol; 2021 Sep; 38(5):83-89. PubMed ID: 34147303
[TBL] [Abstract][Full Text] [Related]
13. Thoracic SMARCA4-deficient undifferentiated tumor with associated granulomatous reaction and response to pembrolizumab.
Marshall M; Khader S; Beasley S; Lajara S
Diagn Cytopathol; 2023 Oct; 51(10):E287-E293. PubMed ID: 37350425
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib-a case report.
Li YF; Zhao XF; Tian Y; Xiao XY; Yan CY; Shen H
Front Genet; 2022; 13():949989. PubMed ID: 35938033
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological characteristics and treatment outcomes of advanced SMARCA4-deficient thoracic tumors.
Wang A; Jin Y; Cao Z; Lu L; Li Z
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38124509
[TBL] [Abstract][Full Text] [Related]
16. Thorahcic SMARCA4-deficient undifferentiated tumors with ganglioneuroma and enchondroma: implications for SLC7A11 and ARID1A expression: a case report.
Kito Y; Kawashima K; Saigo C; Hasegawa M; Nomura S; Mikamo T; Hanamatsu Y; Matsuo Y; Takeuchi T
Diagn Pathol; 2022 Feb; 17(1):29. PubMed ID: 35151345
[TBL] [Abstract][Full Text] [Related]
17. Thoracic SMARCA4-Deficient Undifferentiated Tumors With Unusual Presentations: A Case Series.
Helmink AJ; Alshomrani A; Lauer SR; Yuil-Valdes A
Int J Surg Pathol; 2023 Oct; ():10668969231206350. PubMed ID: 37903457
[TBL] [Abstract][Full Text] [Related]
18. Thoracic SMARCA4-deficient undifferentiated tumor.
Jiang J; Chen Z; Gong J; Han N; Lu H
Discov Oncol; 2023 Apr; 14(1):51. PubMed ID: 37115343
[TBL] [Abstract][Full Text] [Related]
19. SMARCA4-Deficient Undifferentiated Tumor of the Esophagus: Diagnostic Pitfalls in Immunohistochemical Profiles.
Chakrabarti R; Lin S; Wang H; Cecchini M
Int J Surg Pathol; 2024 Mar; ():10668969241228290. PubMed ID: 38497146
[TBL] [Abstract][Full Text] [Related]
20. Thoracic SMARCA4-Deficient Undifferentiated Tumor With
Sheng J; Han W; Pan H
JTO Clin Res Rep; 2023 Apr; 4(4):100476. PubMed ID: 36969551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]